Generation Next
In Stroke Therapeutics

Stroke is a silent killer, striking men and women of any age. Symptoms often go unnoticed for hours. Meanwhile, damage to the brain becomes more permanent, even fatal. If stroke victims get to a hospital, there are few treatment options. Survivors face staggering medical bills, rigorous rehabilitation, missed work, and a life forever altered. Zocere, Inc. wants to change this. We are developing generation next of stroke therapeutics. One of our drugs has the potential of being the first neuro-protectant on the market. Halting damage. Saving lives. We want to tell you about it.

brain

opportunity

Stroke is the second leading cause of death worldwide, claiming more than 130,000 lives each year in the United States alone. It’s also the leading cause of long-term disability. In 2010, the cost of health care, medications, and missed work in the U.S. was $73.7 billion. Stroke is not an old person’s disease either; it can strike at any age. Death rates are higher for African-Americans, Hispanics and Native Americans than whites.

Current treatment options for stroke are too little, too late. This is particularly true for blood clot-induced ischemic stroke—which account for 87 percent of strokes. It’s been almost 20 years since Activase® (altiplase/tPA) was launched as a treatment for ischemic stroke. Few patients benefit from Activase, mainly because they don’t get to the hospital in time for the drug’s narrow treatment window.

All this may be changing, and in the process, creating a unique opportunity. Zocere, Inc. is developing a post-stroke injectable drug designed to protect patients from brain injury by arresting the progression of neurological damage caused by reduced blood flow. Our goal is to reduce deaths, long-term disability and the financial impact of stroke. Thus far, our research is promising. If we are successful—and we are working hard at it—our drug will be the first and possibly only neuro-protectant injectable therapy in the market.

“There is a significant lack of effective stroke therapies. Filling the gap in treatment represents a significant opportunity for patients, physicians, drug developers, and investors.”

Wayne Laslie, CEO
Zocere, Inc.
technology

More than eighty percent of all stroke cases are ischemic insults caused by blocked blood flow and oxygen deprivation to a focal brain area, typically due to a blood clot. Ischemia leads to massive cell death resulting in an irreversibly damaged infarct core with surrounding, potentially salvageable area called the penumbra. Reperfusion* with tPA is the only pharmacologic therapy. However, rapid reperfusion, although necessary for the restoration of brain metabolic activity, comes with additional health risks.

The development of neuro-protection strategies is badly needed to protect brain cells from both ischemia and reperfusion injury and to increase the time window for thrombolytic treatment. A number of cellular and molecular mechanisms have been studied, but none have provided a solution.

Zocere, Inc.’s drug is a derivative of the brain-specific STEP protein tyrosine phosphatase, which is an important downstream regulator of NMDAR-dependent neuronal injury. Other studies that have examined the importance of NMDAR blockade as a strategy for ischemic stroke treatment have failed. Our technology is different. By targeting downstream signaling, molecules that are activated following NMDAR stimulation may protect neurons from damage and obviate the deleterious consequences of NMDAR antagonism. This is a significant advancement.

Our stroke drug candidate is a cell-permeable recombinant peptide that has been overexpressed in E. coli and purified using standard laboratory procedures. The peptide can cross the blood-brain barrier, is resistant to degradation, and can bind constitutively to its substrates. It has been demonstrated in rodent models of transient ischemic stroke that intravenous administration of the peptide will significantly reduce brain damage. This promising new tool for ischemic stroke therapy has the potential to be the first neuro-protectant drug in the market.

* Tissue damage caused when blood supply returns to the tissue after a period of ischemia or lack of oxygen.

“The development of neuro-protection strategies is badly needed to shield neurons from both ischemia and reperfusion injury and widen the time window for thrombolytic treatment.”

Surojit Paul, PhD
Inventor & Associate Professor
Department of Neurology
University of New Mexico

Patents

  • Patents filed in major markets
  • Option to exclusive license to patent

For additional information on our technology, contact us.

partners

No one understands the critical need for more effective stroke therapies better than the pharmaceutical industry. Current therapies are often too little, too late or “last ditch efforts” and not widely in use.

Zocere, Inc.’s injectable brain-specific STEP peptide-based drug is designed to protect patients from brain injury and arrest the progression of neurological damage after an ischemic stroke. Research to date is encouraging. However, to accelerate the development and commercialization process, we are seeking synergistic partners within the pharmaceutical industry who bring financial support, expertise, and resources to continue validation of our protein, advance our IND application and FDA approval, and thus accelerate commercialization.

The ideal strategic partners are:

  • Pharmaceutical companies with an interest or current position in neurological disorders and disease.
  • Clinical research organizations
  • Consulting groups experienced in working with pre-clinical drug companies

If you are interested in becoming an active partner in Zocere, Inc.’s generation next in stroke therapy, we encourage you to contact us to discuss partnership opportunities in more detail.

“Our goal is to attract a pharmaceutical partner who can bring research and monetary resources to accelerate our path to IND and FDA approval.”

Wayne Laslie, CEO
Zocere, Inc.
about

Zocere, Inc. is a New Mexico-based biotech company that is developing novel therapeutics for neurological diseases, including stroke, and offering services to other entities developing stroke-related diagnostics and treatments. We have licensed patented technology for a derivative of the brain-specific  STEP protein, tyrosine phosphatase, developed at the University of New Mexico. This technology is the foundation for a novel, generation next therapeutic treatment of stroke that shows promise of becoming the first injectable neuroprotectant drug in the market.

Leadership Team

wayne-laslie

Wayne Laslie President and CEO

Wayne Laslie has more than 30 years of experience in pharmaceutical commercialization in U.S. and international markets.
He has served in positions of clinical development, business development and commercial development, along with sales, marketing and operations. Prior to joining Zocere, Inc., Laslie held increasingly responsible positions at Pfizer and predecessor companies of Sanofi-Aventis (now Sanofi); was executive vice president at Otsuka America Pharmaceuticals, and most recently he was the chief operating officer at Myriad Pharmaceuticals and Myrexis. Laslie is a former board member of the National Pharmaceutical Council and a past member of the University of Maryland’s Chancellor’s Advisory Committee.
alan-kolod

Alan Kolod, CPA, MBA Chief Financial Officer

Alan Kolod has more than 35 years of experience in finance, accounting and strategic planning for technology-oriented companies.
He has worked with companies in the U.S., Europe and Latin America, building a proven track record of establishing financial infrastructures used to improve operating results and springboard periods of rapid growth. The former CFO of Future Medical Systems Group, Kolod is a Certified Public Accountant and holds an MBA.

alan-kolod

Kenton H. Zavitz, PhD Chief Scientific Officer

Kenton H. Zavitz, PhD, has more than 15 years of biotechnology and pharmaceutical experience, ranging from drug discovery and clinical development to pre-commercialization.
In 1998, Zavitz joined Myriad Genetics, Inc. in Salt Lake City and worked for its subsidiary Myriad Pharmaceuticals, Inc. (later spun out as an independent public company and renamed Myrexis, Inc.). During his tenure with Myriad/Myrexis, Zavitz served as senior director of Clinical Affairs, chief scientist of the tarenflurbil clinical development program (an investigational drug for treating Alzheimer’s disease, developed through Phase 3), director of Neurodegeneration Therapeutics Discovery, director of Strategic In-licensing and Scientific Evaluation, and head of Drug Target Discovery and Validation. He has worked on the development of new drug products in various therapeutic areas, including Alzheimer’s disease, acute pain, HIV, oncology, and inflammatory diseases.

Meet Zocere’s Board of Directors
“We’ve coupled a strong leadership team and board to accelerate the development and commercialization pathways of our stroke therapeutics with a tight financial strategy to leverage investment capital.” Wayne Laslie, CEO Zocere, Inc.

asa Proud supporter of the American Stroke Association

news

We are focused on advancing our technology, establishing industry partnerships and securing investment in our company. Please check here often for news on our activities and progress. If you have questions, insight you'd like to share or if you are a member of the media and would like to request an interview, we encourage you to contact us. Conversations are always welcome.


POSTED: November 14, 2014

Zocere to Present at Landmark Angels’ Investing for Cures: 2020 Foresight

NEW YORK CITY, November 14, 2014 – – Zocere, Inc., a New Mexico-based pharmaceutical company developing a biologic-based neuroprotectant drug for ischemic stroke, will be presenting at Investing for Cures: 2020 Foresight in New York Wednesday, November 19. Hosted by Greenwich, Connecticut-based Landmark Angels, a private angel investment group, Investing (continued…)

Continue Reading


POSTED: November 14, 2014

Zocere Showcases “Brain Saving” Drug at Life Sciences Summit in New York City

NEW YORK CITY, October 14, 2014 – – It happens all too often; people struck by a “silent killer” that can leave them with permanent disabilities or dead. That silent killer is stroke and each year there are an estimated 750,000 acute ischemic strokes in the United States and more (continued…)

Continue Reading


POSTED: September 30, 2014

Zocere’s Laslie to Present Stroke Drug at BIO Investor Forum

SAN FRANCISCO, October 1, 2014 – – Each year an estimated 750,000 American suffer an acute ischemic stroke yet only three to five percent receive pharmacologic treatment because of risks associated with current therapies. New Mexico-based pharmaceutical company Zocere has a “brain protecting” drug it believes has the potential to (continued…)

Continue Reading


Media Inquiries

Melanie Lux Lux + Associates, Inc. 803.331.4794 mlux@luxandassociates.com
contact

Zocere, Inc. is generation next in stroke therapeutics. If you’re interested in learning more about our research and the neuro-protectant stroke drug we have in development, or you’d like to discuss investment and partnership opportunities, we encourage you to contact us.


Find Us

Zocere, Inc.
801 University Blvd., SE
Suite 100
Albuquerque, NM 87106
Wayne Laslie, CEO
Zocere, Inc.
505.272.7041
wayne.laslie@gmail.com


View Map






captcha